Unique ID issued by UMIN | UMIN000021044 |
---|---|
Receipt number | R000023592 |
Scientific Title | The Healing Effects of Platelet- Rich Plasma on refractory cutaneous uclers |
Date of disclosure of the study information | 2016/02/17 |
Last modified on | 2017/08/19 18:16:56 |
The Healing Effects of Platelet- Rich Plasma on refractory cutaneous uclers
The Healing Effects of Platelet- Rich Plasma on refractory cutaneous uclers
The Healing Effects of Platelet- Rich Plasma on refractory cutaneous uclers
The Healing Effects of Platelet- Rich Plasma on refractory cutaneous uclers
Japan |
refractory cutaneous uclers
Dermatology | Plastic surgery |
Others
NO
The purpose of this study is to examine the efficacy and safety of the treatment using the platelet-rich plasma(PRP) to intractable skin ulcers.
Safety,Efficacy
Time to wound closure (days)
We evaluate the length of time (days) from the administration of PRP to full-epithelialization or to when the wound become closed by a simple surgical closure.
We evaluate side reaction such as wound healing delayed, excessive inflammation about treatment with platelet-rich plasma.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Other |
<platelet-rich plasma>
We administer PRP(1-several cc)to the wound in a single dose according to size of the wounded area and evaluate effect of treatment at 1,2,4,6 and 8 weeks after initiation of the therapy. Additional administration of PRP is considered after having obtained patient's consent after start of therapy depending on a state of the wounded area every two weeks. As for the observation and the duration of treatment, we do it with eight weeks, but extend this period to limit in 16 weeks when it shows an effect, and subjects hope for continuation of this treatment.
18 | years-old | <= |
Not applicable |
Male and Female
1)Patients aged 18 over or older at informed consent.Written informed consent.
2)Patient with intractable cutaneous ulcer without the improvement or with the exacerbation by a conventional therapy.
3)Patients who have difficulty in treatment with surgery due to physical states.
4)Patients during ambulatory care,
1) Patients with severe anemia (7 g/dl of Hb or less)
2)Patients with thrombocytopenia(less than Plt 150,000/ul)
3)Other patients judged by the investigator to be inappropriate as subjects of this study.
4)The hospitalized patients.
15
1st name | |
Middle name | |
Last name | Kazuhiko Takehara |
Kanazawa University
Department of Dermatology
13-1 Takaramachi,Kanazawa,Ishikawa
07622652342
hifuka-jimu@med.kanazawa-u.ac.jp
1st name | |
Middle name | |
Last name | Akito Komuro |
Kanazawa University
Division of Plastic and Reconstructive Surgery,Department of Dermatology
13-1 Takaramachi,Kanazawa,Ishikawa
07622652342
komuro@kanazawa-med.ac.jp
Kanazawa University
Kanazawa University
Self funding
NO
2016 | Year | 02 | Month | 17 | Day |
Unpublished
Terminated
2014 | Year | 10 | Month | 28 | Day |
2015 | Year | 02 | Month | 23 | Day |
2016 | Year | 02 | Month | 16 | Day |
2017 | Year | 08 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023592
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |